Lundbeck and Otsuka win FDA approval for schizophrenia drug
Danish pharmaceutical firm Lundbeck and its Japanese partner, Otsuka Pharmaceutical, has gotten the green light from the US Food and Drug Administration to market Abilify Asimtufii.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.